Skip to main content
SpringerLink
Log in

In patients receiving end-of-life care, medications used to treat co-morbid diseases should be discontinued when appropriate

  • Practical Issues & Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Pharmacological treatment in end-of-life care should focus on minimizing symptoms and relieving suffering. Therefore, the continued use of chronic medications for co-morbid conditions should be evaluated on an individualized basis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van Nordennen RT, Lavrijsen JC, Vissers KC, et al. Decision making about change of medication for comorbid disease at the end of life: an integrative review. Drugs Aging. 2014;31(7):501–12.

    Article  PubMed  Google Scholar 

  2. Van Mechelen W, Aertgeerts B, De Ceulaer K, et al. Defining the palliative care patient: a systematic review. Palliat Med. 2013;27(3):197–208.

    Article  PubMed  Google Scholar 

  3. Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singapore Med J. 2002;43(6):279–83.

    CAS  PubMed  Google Scholar 

  4. Sepulveda C, Marlin A, Yoshida T, et al. Palliative care: the World Health Organization’s global perspective. J Pain Symptom Manag. 2002;24(2):91–6.

    Article  Google Scholar 

  5. Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–8.

    Article  PubMed  Google Scholar 

  6. McLean S, Sheehy-Skeffington B, O’Leary N, et al. Pharmacological management of co-morbid conditions at the end of life: is less more? Ir J Med Sci. 2012;182(1):107–12.

    Article  PubMed  Google Scholar 

  7. Silveira MJ, Kazanis AS, Shevrin MP. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med. 2008;11(5):685–93.

    Article  PubMed  Google Scholar 

  8. Bayliss EA, Bronsert MR, Reifler LM, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412–8.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Currow DC, Stevenson JP, Abernethy AP, et al. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55(4):590–5.

    Article  PubMed  Google Scholar 

  10. Parsons C, Hughes CM, Passmore AP, et al. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010;27(6):435–49.

    Article  PubMed  Google Scholar 

  11. Stevenson J, Abernethy AP, Miller C, et al. Managing comorbidities in patients at the end of life. BMJ. 2004;329(7471):909–12.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Legault S, Tierney S, Senecal I, et al. Evaluation of a thromboprophylaxis quality improvement project in a palliative care unit. J Pain Symptom Manag. 2011;41(3):503–10.

    Article  Google Scholar 

  13. Kierner KA, Gartner V, Schwarz M, et al. Use of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care, and anticoagulation. Am J Hosp Palliat Care. 2008;25(2):127–31.

    Article  PubMed  Google Scholar 

  14. Gillon S, Noble S, Ward J, et al. Primary thromboprophylaxis for hospice inpatients: who needs it? Palliat Med. 2011;25(7):701–5.

    Article  PubMed  Google Scholar 

  15. Soto-Cardenas MJ, Pelayo-Garcia G, Rodriguez-Camacho A, et al. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med. 2008;22(8):965–8.

    Article  CAS  PubMed  Google Scholar 

  16. Tran QN. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer. Am J Hosp Palliat Care. 2010;27(6):416–9.

    Article  PubMed  Google Scholar 

  17. Spiess JL. Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation. J Palliat Med. 2009;12(1):83–7.

    Article  PubMed  Google Scholar 

  18. Angelo M, Ruchalski C, Sproge BJ. An approach to diabetes mellitus in hospice and palliative medicine. J Palliat Med. 2011;14(1):83–7.

    Article  PubMed  Google Scholar 

  19. Vandenhaute V. Palliative care and type II diabetes: a need for new guidelines? Am J Hosp Palliat Care. 2010;27(7):444–5.

    Article  PubMed  Google Scholar 

  20. Ford-Dunn S, Smith A, Quin J. Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK. Palliat Med. 2006;20(3):197–203.

    Article  CAS  PubMed  Google Scholar 

  21. Tice MA. Diabetes management at the end of life: transitioning from tight glycemic control to comfort. Home Healthc Nurse. 2006;24(5):290–3.

    Article  PubMed  Google Scholar 

  22. Stiel S, Krumm N, Pestinger M, et al. Antibiotics in palliative medicine: results from a prospective epidemiological investigation from the HOPE survey. Support Care Cancer. 2012;20(2):325–33.

    Article  PubMed  Google Scholar 

  23. Lam PT, Chan KS, Tse CY, et al. Retrospective analysis of antibiotic use and survival in advanced cancer patients with infections. J Pain Symptom Manag. 2005;30(6):536–43.

    Article  Google Scholar 

  24. Enck RE. Antibiotic use in end-of-life care: a soft line? Am J Hosp Palliat Care. 2010;27(4):237–8.

    Article  PubMed  Google Scholar 

  25. Oh DY, Kim JH, Kim DW, et al. Antibiotic use during the last days of life in cancer patients. Eur J Cancer Care (Engl). 2006;15(1):74–9.

    Article  CAS  Google Scholar 

  26. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med. 2005;8(4):876–81.

    Article  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from Drugs & Aging 2014:31(7):501-12 [1] by salaried/contracted employees of Adis/Springer. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. In patients receiving end-of-life care, medications used to treat co-morbid diseases should be discontinued when appropriate. Drugs Ther Perspect 30, 432–434 (2014). https://doi.org/10.1007/s40267-014-0153-1

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-014-0153-1

    Keywords

    Search

    Navigation